We analyzed mRNA expression data from the NeoPalAna trial (GSE93204)30 to assess the associations among MAP3K3 expression, the YAP signature, and drug resistance in patients with luminal breast cancer (Fig. 4p). The gene discussed is YAP1; the disease is breast carcinoma.